Literature DB >> 16316397

Human parvovirus B19: a new emerging pathogen of inflammatory cardiomyopathy.

C-T Bock1, K Klingel, S Aberle, A Duechting, A Lupescu, F Lang, R Kandolf.   

Abstract

The human parvovirus B19 (PVB19), an erythrovirus causing diverse clinical manifestations ranging from asymptomatic or mild to more severe outcomes such as hydrops fetalis, is the only known human pathogenic parvovirus so far. Although enteroviruses have long been considered the most common cause of inflammatory cardiomyopathy, PVB19 is emerging as a important candidate. Recent studies have indicated an association of PVB19 with paediatric and adult inflammatory cardiac disease. However, whether or not PVB19 has an impact on inflammatory cardiomyopathy in adult patients is still unclear. The first hints for a possible aetiopathogenetic role of the PVB19-infection and the development of cardiac dysfunction were demonstrated by molecular biology utilizing in situ hybridization (ISH) and polymerase chain reaction (PCR). According to available evidence, PVB19-associated inflammatory cardiomyopathy is characterized by infection of endothelial cells of small intracardiac arterioles and venules, which may be associated with endothelial dysfunction, impairment of myocardial microcirculation, and penetration of inflammatory cells into the myocardium.

Entities:  

Mesh:

Year:  2005        PMID: 16316397     DOI: 10.1111/j.1439-0450.2005.00867.x

Source DB:  PubMed          Journal:  J Vet Med B Infect Dis Vet Public Health        ISSN: 0931-1793


  16 in total

Review 1.  Cardiovascular inflammation: RNA takes the lead.

Authors:  Colton R Martens; Shyam S Bansal; Federica Accornero
Journal:  J Mol Cell Cardiol       Date:  2019-03-14       Impact factor: 5.000

2.  miRNA as activity markers in Parvo B19 associated heart disease.

Authors:  U Kühl; M Rohde; D Lassner; U M Gross; F Escher; H-P Schultheiss
Journal:  Herz       Date:  2012-09       Impact factor: 1.443

3.  Parvovirus B19 myocarditis causes significant morbidity and mortality in children.

Authors:  Kimberly M Molina; Xiomara Garcia; Susan W Denfield; Yuxin Fan; William R Morrow; Jeffrey A Towbin; Elizabeth A Frazier; David P Nelson
Journal:  Pediatr Cardiol       Date:  2012-08-08       Impact factor: 1.655

4.  Phospholipase A2 activity-dependent stimulation of Ca2+ entry by human parvovirus B19 capsid protein VP1.

Authors:  Adrian Lupescu; C-Thomas Bock; Philipp A Lang; Susanne Aberle; Heike Kaiser; Reinhard Kandolf; Florian Lang
Journal:  J Virol       Date:  2006-09-06       Impact factor: 5.103

Review 5.  Advances in human B19 erythrovirus biology.

Authors:  Annabelle Servant-Delmas; Jean-Jacques Lefrère; Frédéric Morinet; Sylvie Pillet
Journal:  J Virol       Date:  2010-07-14       Impact factor: 5.103

6.  Molecular phenotypes of human parvovirus B19 in patients with myocarditis.

Authors:  C-Thomas Bock; Anja Düchting; Friederike Utta; Eva Brunner; Bui Tien Sy; Karin Klingel; Florian Lang; Meinrad Gawaz; Stephan B Felix; Reinhard Kandolf
Journal:  World J Cardiol       Date:  2014-04-26

Review 7.  [Molecular mechanisms and consequences of cardiac viral infections].

Authors:  R Kandolf; B Bültmann; K Klingel; C-T Bock
Journal:  Pathologe       Date:  2008-11       Impact factor: 1.011

8.  Human parvovirus B19 VP1u Protein as inflammatory mediators induces liver injury in naïve mice.

Authors:  Tsai-Ching Hsu; Chun-Ching Chiu; Shun-Chih Chang; Hsu-Chin Chan; Ya-Fang Shi; Tzy-Yen Chen; Bor-Show Tzang
Journal:  Virulence       Date:  2015-12-02       Impact factor: 5.882

Review 9.  Viral myocarditis: diagnosis, aetiology and management.

Authors:  Uwe Kühl; Heinz-Peter Schultheiss
Journal:  Drugs       Date:  2009-07-09       Impact factor: 9.546

10.  Human parvovirus B19 NS1 protein modulates inflammatory signaling by activation of STAT3/PIAS3 in human endothelial cells.

Authors:  Anja Duechting; Carsten Tschöpe; Heike Kaiser; Tobias Lamkemeyer; Nobuyuki Tanaka; Susanne Aberle; Florian Lang; Joseph Torresi; Reinhard Kandolf; C-Thomas Bock
Journal:  J Virol       Date:  2008-06-11       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.